NASDAQ:PBM Psyence Biomedical (PBM) Stock Price, News & Analysis $6.31 +0.21 (+3.44%) Closing price 09/23/2026 04:00 PM EasternExtended Trading$6.42 +0.12 (+1.82%) As of 05:41 AM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more. Add Compare Share Share Stock Analysis Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFDA EventsFinancialsNews and TrendsOwnershipSEC Filings About Psyence Biomedical Stock (NASDAQ:PBM) View Price History Chart DataSkip Price History Chart 1 Day 5 Days 30 Days 90 Days 1 Year Advanced 1 Day 1 Day 5 Days 30 Days 90 Days 1 Year Advanced Show volume Show extended hours Get Psyence Biomedical alerts:Sign Up Key Stats Today's Range$5.87▼$7.1950-Day Range$2.82▼$6.6352-Week Range$1.92▼$28.13Volume293,841 shsAverage Volume68,218 shsMarket Capitalization$14.45 millionP/E Ratio0.25Dividend YieldN/APrice TargetN/AConsensus RatingSell Company Overview Psyence Biomedical Ltd. (NASDAQ: PBM) is a clinical-stage biotechnology company focused on developing psychedelic-based therapeutics for mental health conditions. The company’s research centers on naturally derived psilocybin and its potential use in medically supervised treatment programs. Its lead development program is designed to evaluate psilocybin-assisted therapy for adjustment disorder in patients with cancer. Psyence Biomedical’s activities include drug development, clinical research and work with external partners to advance psychedelic medicines toward potential regulatory approval and commercialization. The company became publicly traded on Nasdaq in February 2024 following a business combination with Newcourt Acquisition Corp. Psyence Biomedical is part of the broader Psyence Group, which has pursued psychedelic medicine research and development internationally. As a clinical-stage company, its programs remain subject to clinical, regulatory and commercial uncertainties.AI Generated. May Contain Errors. Read More Psyence Biomedical Stock Analysis - MarketRank™See Top-Rated MarketRank™ Stocks26th Percentile Overall ScorePBM MarketRank™: Psyence Biomedical scored higher than 26% of companies evaluated by MarketBeat, and ranked 789th out of 897 stocks in the healthcare sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation. Analyst's Opinion0.7 / 5Analyst RatingSell Consensus RatingPsyence Biomedical has received a consensus rating of Sell. The company's average rating score is 1.00, and is based on no strong buy ratings, no buy ratings, no hold ratings, and 1 sell rating.Amount of Analyst CoveragePsyence Biomedical has only been the subject of 1 research reports in the past 90 days.Read more about Psyence Biomedical's stock forecast and price target. Earnings and Valuation1.9 / 5Proj. Earnings GrowthN/A Price to Earnings Ratio vs. the MarketThe P/E ratio of Psyence Biomedical is 0.25, which means that it is trading at a less expensive P/E ratio than the market average P/E ratio of about 39.00.Price to Earnings Ratio vs. SectorThe P/E ratio of Psyence Biomedical is 0.25, which means that it is trading at a less expensive P/E ratio than the Healthcare sector average P/E ratio of about 274.09.Price to Book Value per Share RatioPsyence Biomedical has a P/B Ratio of 0.85. P/B Ratios below 1 indicate that a company could be undervalued with respect to its assets and liabilities. Short Interest4.0 / 5Short Interest LevelHealthy Percentage of Shares Shorted0.63% of the float of Psyence Biomedical has been sold short.Short Interest Ratio / Days to CoverPsyence Biomedical has a short interest ratio ("days to cover") of 0.1, which is generally considered an acceptable ratio of short interest to trading volume.Change versus previous monthShort interest in Psyence Biomedical has recently decreased by 2.98%, indicating that investor sentiment is improving. Dividend0.0 / 5Dividend StrengthN/A Dividend YieldPsyence Biomedical does not currently pay a dividend.Dividend GrowthPsyence Biomedical does not have a long track record of dividend growth. News and Social Media2.1 / 5News Sentiment0.41 News SentimentPsyence Biomedical has a news sentiment score of 0.41. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This news sentiment score is similar to the average news sentiment of Healthcare companies.News Coverage This WeekMarketBeat has tracked 5 news articles for Psyence Biomedical this week, compared to 3 articles on an average week.Search InterestOnly 2 people have searched for PBM on MarketBeat in the last 30 days. This is a decrease of -67% compared to the previous 30 days. Company Ownership0.8 / 5Insider TradingN/A Insider Buying vs. Insider SellingIn the past three months, Psyence Biomedical insiders have not sold or bought any company stock.Percentage Held by Insiders3.60% of the stock of Psyence Biomedical is held by insiders.Percentage Held by Institutions77.44% of the stock of Psyence Biomedical is held by institutions. High institutional ownership can be a signal of strong market trust in this company.Read more about Psyence Biomedical's insider trading history. Receive PBM Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Psyence Biomedical and its competitors with MarketBeat's FREE daily newsletter. Submit View SMS TermsSMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. PBM Stock News HeadlinesPsyence To Initiate Share Exchange With PsyLabs To Advance Ibogaine; Stock Up4 hours ago | rttnews.comPsyence BioMed Agrees Up to $5 Million PsyLabs Investment and Forms Texas Ibogaine UnitSeptember 23 at 3:01 PM | finance.yahoo.comMILLIONAIRE MASTERCLASS INVITE: AltucherJames Altucher says Elon Musk is preparing an unprecedented project set to surface on September 25. Altucher is hosting a free masterclass revealing what he says is locked inside a sealed briefcase detailing Musk's plans. Attendees who join early can also access a $1,000 bonus offer included with the presentation. | Paradigm Press (Ad)Psyence Biomedical Launches Texas Ibogaine Unit and Commits Up to US$5 Million in PsyLabsSeptember 23 at 7:30 AM | tipranks.comPsyence BioMed Announces Strategic Ibogaine InvestmentSeptember 23 at 7:00 AM | globenewswire.comPsyence Biomedical (NASDAQ:PBM) Shares Up 4.9% - Here's WhySeptember 19, 2026 | americanbankingnews.comPsyence BioMed Establishes Texas Entity To Advance U.S. Ibogaine DevelopmentSeptember 14, 2026 | rttnews.comPsyence BioMed Launches Texas Ibogaine Research Unit to Drive U.S. Neuroplastogen DevelopmentSeptember 14, 2026 | tipranks.comSee More Headlines PBM Stock Analysis - Frequently Asked Questions How have PBM shares performed this year? Psyence Biomedical's stock was trading at $4.7088 at the beginning of 2026. Since then, PBM shares have increased by 34.0% and is now trading at $6.31. How were Psyence Biomedical's earnings last quarter? Psyence Biomedical Ltd. (NASDAQ:PBM) released its earnings results on Thursday, January, 23rd. The company reported $25.40 earnings per share (EPS) for the quarter. When did Psyence Biomedical's stock split? Psyence Biomedical shares reverse split on the morning of Monday, May 5th 2025.A 100-797 reverse split was announced. The number of shares owned by shareholders was adjusted after the market closes on Sunday, May 4th 2025. An investor that had 100 shares of stock prior to the reverse split would have 13 shares after the split. How do I buy shares of Psyence Biomedical? Shares of PBM stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. What other stocks do shareholders of Psyence Biomedical own? Based on aggregate information from My MarketBeat watchlists, some other companies that Psyence Biomedical investors own include BlackRock ESG Capital Allocation Term Trust (ECAT), Barings Global Short Duration High Yield Fund (BGH), BlackRock Innovation and Growth Term Trust (BIGZ), BlackRock Health Sciences Term Trust (BMEZ), BlackRock Science and Technology Term Trust (BSTZ) and Cameco (CCJ). Company Calendar Last Earnings1/23/2025Today9/23/2026Fiscal Year End3/31/2027Get Stock Alerts Health Indicator TradeSmith's Health IndicatorA long-term volatility-based measure designed for securities held 12 months or longer.Green: Strong and healthy uptrend with normal pullbacks.Yellow: Significant pullback but still within expected volatility.Red: Dropped beyond expected volatility; considered unhealthy. Green Zone (2w+) 1-Year History Sep 25 Dec 25 Mar 26 Jun 26 Sep 26 For the last 2 weeks, PBM's financial health has been in the Green zone, according to TradeSmith. Industry, Sector and Symbol Stock ExchangeNASDAQ SectorHealthcare Industry Pharmaceuticals Sub-IndustryPharmaceuticals Current SymbolNASDAQ:PBM Previous SymbolNASDAQ:PBM CIK1985062 Webwww.psyence.com Phone510-214-3750FaxN/AEmployees12Year FoundedN/AProfitability EPS (Trailing Twelve Months)N/A Trailing P/E Ratio0.25 Forward P/E RatioN/A P/E GrowthN/ANet IncomeN/A Net MarginsN/A Pretax MarginN/A Return on EquityN/A Return on AssetsN/A Debt Debt-to-Equity RatioN/A Current Ratio14.62 Quick Ratio14.62 Sales & Book Value Annual SalesN/A Price / SalesN/A Cash FlowN/A Price / Cash FlowN/A Book Value$7.39 per share Price / Book0.85Miscellaneous Outstanding Shares2,290,000Free Float2,210,000Market Cap$14.45 million OptionableN/A Beta1.72 10 Stocks Powering The Next AI Boom The AI boom is creating opportunities across semiconductors, cloud computing, enterprise software, infrastructure, cybersecurity, and automation. Inside this report, you’ll find 10 companies positioned to benefit as artificial intelligence moves from hype to real-world deployment and becomes a core growth driver for corporate America.Get This Free Report This page (NASDAQ:PBM) was last updated on 9/24/2026 by MarketBeat.com Staff. From Our PartnersHow to get a stake in Anthropic — before the IPOAnthropic, the maker of Claude AI, has reportedly filed for an IPO that could arrive as early as October. Its ...Weiss Ratings | SponsoredWhy I believe the AI market will split in Q4Matt McCall, who recommended Nvidia near $6 a share, says the AI market is splitting in two - just like the do...The Oxford Club | SponsoredShocking new footage just releasedGerardo Del Real is calling it the Third Convergence Event, a new catalyst hitting the uranium market that he ...Digest Publishing | SponsoredBarricks gold output fell from 2 million ounces to 719000Barrick's gold production has plunged from 2 million ounces to just 719,000, leaving the world's second-larges...Golden Portfolio | SponsoredMajor Buy Alert Issued for September 30thKeith Kaplan has invested $17 million into his own AI research tools, building a platform now used by 180,000 ...TradeSmith | SponsoredIf you keep cash in a U.S. bank account… read this NOWSince 2020, U.S. banks have been required to keep zero percent of deposits on hand, lending out nearly every d...Banyan Hill Publishing | SponsoredHere’s the stock symbol I’ve promisedWhitney Tilson of Stansberry Research has long recommended Berkshire Hathaway as a core retirement holding - b...Stansberry Research | SponsoredTrump's New DollarPorter Stansberry says President Trump has signed an executive order initiating what he calls a full U.S. doll...Porter & Company | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Psyence Biomedical Ltd. Please log in to your account or sign up in order to add this asset to your watchlist. Share Psyence Biomedical With A Colleague Link copied to clipboard. Unlock superior investment research and tools. Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools and reports. Get MarketBeat All Access MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
